Prevalence of renal dysfunction in tacrolimus-treated pediatric transplant recipients: A systematic review

Pediatric Transplantation

Volumn 17, Issue 3, 2013, Pages 205-215

  Gijsen, Violette M G J ^a,b   Hesselink, Dennis A ^c   Croes, Kenneth ^a   Koren, Gideon ^b,d   De Wildt, Saskia N ^a  

^a SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

children; non renal transplantation; renal dysfunction; tacrolimus

Indexed keywords

CYCLOSPORIN; TACROLIMUS;

CHILD; CHRONIC KIDNEY DISEASE; DISEASE SEVERITY; FOLLOW UP; GRAFT RECIPIENT; HEART GRAFT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTESTINE GRAFT; LIVER GRAFT; LUNG TRANSPLANTATION; PREVALENCE; QUALITY CONTROL; REVIEW; SYSTEMATIC REVIEW;

CHILD; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY DISEASES; ORGAN TRANSPLANTATION; PREVALENCE; RISK FACTORS; TACROLIMUS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84876731437     PISSN: 13973142     EISSN: 13993046     Source Type: Journal    
DOI: 10.1111/petr.12056     Document Type: Review

References (47)

1. Ojo AO, Held PJ, Port FK, et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 2003: 349: 931-940.
2. Kearns GL, Abdel-Rahman SM, Alander SW, et al. Developmental pharmacology-drug disposition, action, and therapy in infants and children. N Engl J Med 2003: 349: 1157-1167.
3. Rhodin MM, Anderson BJ, Peters AM, et al. Human renal function maturation: A quantitative description using weight and postmenstrual age. Pediatr Nephrol 2009: 24: 67-76.
4. Chen N, Aleksa K, Woodland C, Rieder M, Koren G,. Ontogeny of drug elimination by the human kidney. Pediatr Nephrol 2006: 21: 160-168.
5. Tetelbaum M, Finkelstein Y, Nava-Ocampo AA, Koren G,. Back to basics: Understanding drugs in children: Pharmacokinetic maturation. Pediatr Rev 2005: 26: 321-328.
6. Chandrakantan A, De Mattos AM, Naftel D, Crosswy A, Kirklin J, Curtis JJ,. Increasing referral for renal transplant evaluation in recipients of nonrenal solid-organ transplants: A single-center experience. Clin J Am Soc Nephrol 2006: 1: 832-836.
7. Astellas Pharma Canada Inc. Product Monograph Prograf (tacrolimus). 2005.
8. Staatz CE, Goodman LK, Tett SE,. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part I. Clin Pharmacokinet 2010: 49: 141-175.
9. Naesens M, Kuypers DRJ, Sarwal M,. Calcineurin inhibitor nephrotoxicity. Clin J Am Soc Nephrol 2009: 4: 481-508.
10. Matas AJ,. Calcineurin inhibitors: Short-term friend, long-term foe? Clin Pharmacol Ther 2011: 90: 209-211.
11. Nankivell BJ, Borrows RJ, Fung CL-S, O'Connell PJ, Allen RDM, Chapman JR,. The natural history of chronic allograft nephropathy. N Engl J Med 2003: 349: 2326-2333.
12. Nankivell BJ, Borrows RJ, Fung CLS, O'Connell PJ, Chapman JR, Allen RDM,. Calcineurin inhibitor nephrotoxicity: Longitudinal assessment by protocol histology. Transplantation 2004: 78: 557-565.
13. Chapman JR,. Chronic calcineurin inhibitor use is nephrotoxic. Clin Pharmacol Ther 2011: 90: 207-209.
14. Neu AM, Ho PLM, Fine RN, Furth SL, Fivush BA,. Tacrolimus vs. cyclosporine A as primary immunosuppression in pediatric renal transplantation: A NAPRTCS study. Pediatr Transplant 2003: 7: 217-222.
15. Jain S, Bicknell GR, Nicholson ML,. Tacrolimus has less fibrogenic potential than cyclosporin A in a model of renal ischaemia-reperfusion injury. Br J Surg 2000: 87: 1563-1568.
16. Webster AC, Woodroffe RC, Taylor RS, Chapman JR, Craig JC,. Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: Meta-analysis and meta-regression of randomised trial data. BMJ 2005: 331: 810.
17. Lamoureux F, Mestre E, Essig M, Sauvage FL, Marquet P, Gastinel LN,. Quantitative proteomic analysis of cyclosporine-induced toxicity in a human kidney cell line and comparison with tacrolimus. J Proteomics 2011: 75: 677-694.
18. Klawitter J, Klawitter J, Kushner E, et al. Association of immunosuppressant-induced protein changes in the rat kidney with changes in urine metabolite patterns: A proteo-metabonomic study. J Proteome Res 2010: 9: 865-875.
19. Von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP,. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: Guidelines for reporting observational studies. J Clin Epidemiol 2008: 61: 344-349.
20. Bishop JR, Burniston MT, Barnfield MC, et al. Renal function evaluated by measured GFR during follow-up in pediatric liver transplant recipients. Pediatr Transplant 2009: 13: 96-103.
21. Loo RM, Ariyarajah V, Oh C, Shen L, Aw MM, Prabhakaran K,. Comparison between effects of cyclosporine and tacrolimus on glomerular filtration rate in pediatric post-orthotopic liver transplant patients. Pediatr Transplant 2006: 10: 55-59.
22. Staatz CE, Taylor PJ, Lynch SV, Tett SE,. A pharmacodynamic investigation of tacrolimus in pediatric liver transplantation. Liver Transpl 2004: 10: 506-512.
23. Colombani PM, Lau H, Prabhakaran K, et al. Cumulative experience with pediatric living related liver transplantation. J Pediatr Surg 2000: 35: 9-12.
24. Wiesmayr S, Jungraithmayr TC, Ellemunter H, et al. Long-term glomerular filtration rate following pediatric liver transplantation. Pediatr Transplant 2005: 9: 604-611.
25. Tumgor G, Arikan C, Kilic M, Aydogdu S,. Frequency of hyperuricemia and effect of calcineurin inhibitors on serum uric acid levels in liver transplanted children. Pediatr Transplant 2006: 10: 665-668.
26. Arora-Gupta N, Davies P, McKiernan P, Kelly DA,. The effect of long-term calcineurin inhibitor therapy on renal function in children after liver transplantation. Pediatr Transplant 2004: 8: 145-150.
27. Calvo-Garcia MA, Campbell KM, O'Hara SM, Khoury P, Mitsnefes MM, Strife CF,. Acquired renal cysts after pediatric liver transplantation: Association with cyclosporine and renal dysfunction. Pediatr Transplant 2008: 12: 666-671.
28. Berg UB, Ericzon BG, Nemeth A,. Renal function before and long after liver transplantation in children. Transplantation 2001: 72: 631-637.
29. Heffron TG, Pillen T, Smallwood GA, Welch D, Oakley B, Romero R,. Pediatric liver transplantation with daclizumab induction. Transplantation 2003: 75: 2040-2043.
30. Cacciarelli TV, Esquivel CO, Cox KL, et al. Oral tacrolimus (FK506) induction therapy in pediatric orthotopic liver transplantation. Transplantation 1996: 61: 1188-1192.
31. Anastaze Stelle K, Belli DC, Parvex P, et al. Glomerular and tubular function following orthotopic liver transplantation in children treated with tacrolimus. Pediatr Transplant 2012: 16: 250-256.
32. Benden C, Kansra S, Ridout DA, et al. Chronic kidney disease in children following lung and heart-lung transplantation. Pediatr Transplant 2009: 13: 104-110.
33. Simmonds J, Dewar C, Dawkins H, Burch M, Fenton M,. Tacrolimus in pediatric heart transplantation: Ameliorated side effects in the steroid-free, statin era. Clin Transplant 2009: 23: 415-419.
34. Di Filippo S, Zeevi A, McDade KK, et al. Impact of TGFbeta1 gene polymorphisms on late renal function in pediatric heart transplantation. Hum Immunol 2005: 66: 133-139.
35. Armitage JM, Fricker FJ, Del Nido P, Starzl TE, Hardesty RL, Griffith BP,. A decade (1982 to 1992) of pediatric cardiac transplantation and the impact of FK 506 immunosuppression. J Thorac Cardiovasc Surg 1993: 105: 464-472, discussion 472-473.
36. Gijsen V, Mital S, Van Schaik RH, et al. Age and CYP3A5 genotype affect tacrolimus dosing requirements after transplant in pediatric heart recipients. J Heart Lung Transplant 2011: 30: 1352-1359.
37. Ueno T, Kato T, Gaynor J, et al. Renal function after pediatric intestinal transplant. Transplant Proc 2006: 38: 1759-1761.
38. Stratta P, Canavese C, Quaglia M, et al. Posttransplantation chronic renal damage in nonrenal transplant recipients. Kidney Int 2005: 68: 1453-1463.
39. Bloom RD, Reese PP,. Chronic kidney disease after nonrenal solid-organ transplantation. J Am Soc Nephrol 2007: 18: 3031-3041.
40. Rahn KH, Heidenreich S, Brückner D,. How to assess glomerular function and damage in humans. J Hypertens 1999: 17: 309-317.
41. Carlsen JE, Møller ML, Lund JO, Trap-Jensen J,. Comparison of four commercial Tc-99 m(Sn)DTPA preparations used for the measurement of glomerular filtration rate: Concise communication. J Nucl Med 1980: 21: 126-129.
42. Schwartz GJ, Brion LP, Spitzer A,. The use of plasma creatinine concentration for estimating glomerular filtration rate in infants, children, and adolescents. Pediatr Clin North Am 1987: 34: 571-590.
43. Schwartz GJ, Work DF,. Measurement and estimation of GFR in children and adolescents. Clin J Am Soc Nephrol 2009: 4: 1832-1843.
44. Filler G, Priem F, Lepage N, et al. Beta-trace protein, cystatin C, beta(2)-microglobulin, and creatinine compared for detecting impaired glomerular filtration rates in children. Clin Chem 2002: 48: 729-736.
45. Filler G, Bendrick-Peart J, Strom T, Zhang YL, Johnson G, Christians U,. Characterization of sirolimus metabolites in pediatric solid organ transplant recipients. Pediatr Transplant 2009: 13: 44-53.
46. Abraham BP, Frazier EA, Morrow WR, et al. Cystatin C and neutrophil gelatinase-associated lipocalin as markers of renal function in pediatric heart transplant recipients. Pediatr Transplant 2011: 15: 564-569.
47. Snanoudj R, Royal V, Elie C, et al. Specificity of histological markers of long-term CNI nephrotoxicity in kidney-transplant recipients under low-dose cyclosporine therapy. Am J Transplant 2011: 11: 2635-2646.